Schrodinger Inc. Stock
€17.80
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Schrodinger Inc.
sharewise wants to provide you with the best news and tools for Schrodinger Inc., so we directly link to the best financial data sources.
Financials
News
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target
Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus kinase (JAK) target. The partnership was
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 21, 2025, the company granted restricted stock units (RSUs) with respect to 7,051 shares of the company’s common stock to seven newly
Schrödinger to Present at Jefferies Global Healthcare Conference
Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference. The live presentation will take place on
Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma
Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association
Schrödinger Reports Strong First Quarter 2025 Financial Results
Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended March 31, 2025.
“We are very pleased with Schrödinger’s performance in the first quarter of 2025, with
Schrödinger to Present at BofA Securities 2025 Healthcare Conference
Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation will take place on
Schrödinger Presents New Preclinical Data at AACR Annual Meeting
Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025
Schrödinger to Announce First Quarter 2025 Financial Results on May 7
Schrödinger (Nasdaq: SDGR) will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close. The company will host a conference call and webcast at
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company’s common stock to one newly